North Point Portfolio Managers Corp OH Grows Stock Position in Boston Scientific Corporation $BSX

North Point Portfolio Managers Corp OH increased its stake in Boston Scientific Corporation (NYSE:BSX) by 42.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 147,327 shares of the medical equipment provider’s stock after buying an additional 43,893 shares during the quarter. North Point Portfolio Managers Corp OH’s holdings in Boston Scientific were worth $9,245,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth about $26,000. Swiss RE Ltd. bought a new position in Boston Scientific during the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific in the 4th quarter worth about $26,000. Bangor Savings Bank raised its position in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the period. Finally, Board of the Pension Protection Fund bought a new stake in Boston Scientific in the fourth quarter worth about $29,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 9,800 shares of company stock valued at $554,012 in the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX stock opened at $42.64 on Wednesday. The company has a market capitalization of $63.38 billion, a P/E ratio of 17.84, a P/E/G ratio of 0.83 and a beta of 0.56. The company’s 50-day simple moving average is $52.04 and its two-hundred day simple moving average is $70.28. Boston Scientific Corporation has a one year low of $42.25 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific declared that its board has approved a share repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

BSX has been the subject of several recent analyst reports. UBS Group dropped their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Truist Financial decreased their price target on Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, June 4th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Mizuho reduced their target price on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $83.36.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific completed its POLARx Post Approval Study, adding fresh clinical data to its atrial fibrillation growth narrative and supporting confidence in its cardiac ablation pipeline. Boston Scientific’s POLARx Study Completion Adds Fresh Data to Atrial Fibrillation Growth Story
• Positive Sentiment: The company’s recent revenue trend remains strong, with Q1 2026 sales of $5.2 billion, up 11.6% year over year, and Wall Street analysts still showing a generally constructive long-term view despite recent stock weakness.
• Neutral Sentiment: Boston Scientific’s $1.5 billion investment in MiRus, along with an option to acquire its TAVR system, signals continued strategic expansion in structural heart and implant technologies. Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option
• Neutral Sentiment: Erste Group trimmed near-term earnings estimates slightly, but the revisions were modest and still aligned with consensus for FY2026, suggesting limited new fundamental change. Boston Scientific analyst estimate update
• Negative Sentiment: Recent analyst downgrades and lower price targets have weighed on sentiment, with concerns centered on softer Watchman demand, procedure bundling, and broader medtech industry pressure. Boston Scientific Stock (BSX) Opinions on Recent Analyst Downgrades
• Negative Sentiment: The stock’s weak technical setup and proximity to multi-year lows are also contributing to selling pressure, as investors remain cautious about the timing of any recovery.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.